Auph short interest.
@PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 - 6 days to cover. From mid-April to mid-May the short position decreased by 2M down to 15.5M, 11% of ...
Aurinia Pharmaceuticals Inc AUPH shares are trading higher, adding to gains of more than 17% over the last week. The stock has been trending higher since the company announced that its ...WebMar 21, 2023 · Biotech stocks are very interest rate sensitive and I suspect once the Federal Reserve pivots and begins cutting interest rates, AUPH and the rest of the sector's stocks will move materially ... AUPH ($8.23) is undervalued by 7.05% relative to our estimate of its Fair Value price of $8.85 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safetyThe SPDR S&P Biotech ETF, one of the largest U.S. biotech ETFs, has a short interest percent of float of 57.7%, according to data from S3 Partners.Get the latest SCYNEXIS Inc (SCYX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Investors in Aurinia Pharmaceuticals (NASDAQ:AUPH) have seen favorable returns of 78% over the past year. Passive investing in index funds can generate returns that roughly …AUPH short interest is 8.5%. Also see, Alnylam Pharma is said to be a potential target for Novartis. Recommended For You. Comments (34) Newest. Publish. Have a tip? Submit confidentially to our ...
Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...Short Interest. Most Shorted. Largest Increase. Largest Decrease. ... The analyst firm set a price target for $15.00 expecting AUPH to rise to within 12 months (a possible 67.41% upside).
The average one-year price target for AUPH / Aurinia Pharmaceuticals Inc is $14.28. The forecasts range from a low of $12.12 to a high of $15.75. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond ...These cookies may be set through our site by us and our advertising partners to make advertising messages more relevant to you. They perform functions like preventing the same ad from continuously reappearing, ensuring that ads are properly displayed for advertisers, selecting advertisements that are based on your interests and measuring the number of …586. -18.84. 2023-11-22. NP. PSGIX - Blackrock Advantage Small Cap Growth Fund Institutional This fund is a listed as child fund of BlackRock Inc. and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value.
Short Float / Ratio: 13.17% / 8.88: Perf Quarter-4.23%: Sales: 158.85M: P/S: 8.19: EPS this Y: 31.36%: Inst Trans: 9.16%: Short Interest: 17.19M: Perf Half Y-5.03%: Book/sh: 2.73: P/B: 3.32: EPS next Y: 29.71%: ROA-14.80%: Target Price: 13.21: Perf Year: 76.61%: Cash/sh: 2.35: P/C: 3.85: EPS next 5Y-ROE-18.94%: 52W Range: 4.07 - 12.43: Perf YTD ...
The u/AnalystRipper community on Reddit. Reddit gives you the best of the internet in one place.
Find out why interest in selling AUPH stock has not subsided in some quarters. ... @PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 ...AUPH opened at $9.06 on Friday. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.07 and a 1 year high of $12.43. The stock’s 50 day simple moving average is $7.93 and its 200 day simple ...AUPH Short Interest SETTLEMENT DATE SHORT INTEREST AVG. DAILY SHARE VOLUME DAYS TO COVER 02/12/2021 5,442,521 4,199,973 1.295847. Reply Like. Delmar Price. 26 Feb. 2021. Investing Group.Aurinia Pharmaceuticals Stock (NASDAQ: AUPH) stock price, news, charts, stock research, ... Profile News Analyst Ratings Guidance Dividends Earnings Insider Trades Ideas …Short interest for Aurinia Pharmaceuticals gives investors a sense of the degree to which investors are betting on the decline of Aurinia Pharmaceuticals's stock. Short interest data is...Aurinia Pharmaceuticals ( NASDAQ: AUPH) rose 6.5% amid renewed takeover speculation. There's speculation than unnamed suitor may be eyeing a takeover of Aurinia ( AUPH ), according to a Betaville ...
In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ...Oct 29, 2021 · Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ: AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers ... The u/AnalystRipper community on Reddit. Reddit gives you the best of the internet in one place.Mar 23, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) rose 6.5% amid renewed takeover speculation. There's speculation than unnamed suitor may be eyeing a takeover of Aurinia ( AUPH ), according to a Betaville ... Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars. 9.28.The settlement with Sun Pharma appeared to spark some renewed speculation that the company could be a takeover target again. Dealreporter speculated at the time that Aurinia (AUPH) could be viewed as a takeout candidate with the patent overhang lifted. Aurinia (AUPH) short interest is 10.7%.AUPH has hovered mostly in the $13's and with a few short lived high's in the $14's and $15's. Has had some pretty volatile swings in single day trading periods.
Jun 29, 2023 · Aurinia Pharmaceuticals (AUPH) has begun to examine strategic alternatives that could include a potential sale or merger. ... Also, with 11%+ short interest, there should be some "motivated ... Aurinia Pharmaceuticals posted its second quarter numbers on August 3rd. The company posted a GAAP loss of 8 cents a share, more than a dime a share better than expectations. Revenues rose 47% on ...
The setup was perfect (IMO) with more than 21% Short Interest, a Put/Call ratio of 0.25 (Dec-2023) and a strong earnings + guidance from a grossly oversold position. Long term Bullish, but I will be waiting for the $3.29 gap fill most likely to re-build, unless the Company can formalize a plan to be NASDAQ compliant in short-order. 1969: CARVAurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus...Short Interest. Prev. Close. Compare to Peers. More on AUPH. Trending Analysis. Trending News. Seeking Alpha - Power to Investors. Power to Investors. Follow us. Download app. Subscription Support ...AUPH | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Jul 15, 2022 · Biogen has more recently been seen as a potential acquirer of AUPH after a Stat News report said that Biogen is working with Goldman Sachs to find potential targets for the company. Aurinia ( AUPH ... Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ:AUPH) rose 2.8% on a report that a European-based investor group is campaigning for the biotech to begin a strategic ...The forecasted annual EBITDA of AUPH / Aurinia Pharmaceuticals Inc in 2025-12-31 is -52MM. EBIDTA is an acronym that stands for earnings before interest, taxes, depreciation, and amortization. Analysts and investors pay attention to EBITDA because it strips out items that a company must report on its balance sheet but doesn’t significantly ...
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars. 9.28.
AUPH short interest is 8.5%. Also see, Alnylam Pharma is said to be a potential target for Novartis. Recommended For You. Comments (34) Newest. Publish. Have a tip? Submit confidentially to our ...
AUPH 4.86%. Apple Inc. $191.24. AAPL 0.68%. Sarepta Therapeutics Inc. ... Earnings before interest, taxes, depreciation, and amortization, is a measure of a company's overall financial performance ...Short Interest: 17.28M (10/31/23)Short Interest Change-0.88%: Percent of Float: 13.23%Mission Statement. The mission of ShortSqueeze® is to provide short interest stock market data and services, so our members will be better informed of short selling in the market, track short interest in stocks, and gain from the advantages of this powerful market data. Tuesday November 28, 2023. 20 Min Delayed.Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ: AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers ...Aug 3, 2023 · 586. -18.84. 2023-11-22. NP. PSGIX - Blackrock Advantage Small Cap Growth Fund Institutional This fund is a listed as child fund of BlackRock Inc. and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value. Aurinia Pharmaceuticals posted its second quarter numbers on August 3rd. The company posted a GAAP loss of 8 cents a share, more than a dime a share better than expectations. Revenues rose 47% on ...AUPH | Aurinia Pharmaceuticals short interest and earnings date annual report Jul, 2023 Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8. Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272. SIC: 2834 - PHARMACEUTICAL PREPARATIONS. State location: A1 | State of Inc.: A0 | …Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...316 K. 119 K. +166%. Loading... Stock Performance by Trading Session. Trading Session Volume Relative to Daily Average. View statistical stock analysis for Aurinia Pharmaceuticals - Common Shares (AUPH). Choose from a list of different historical perspectives such as intraday stock behavior, gap up moves, gap down moves, large …WebIntroduction. This short interest tracker provides a variety of short interest related data, sourced from a variety of partners. The data is organized by frequency of updates, with intraday data at the top (short shares availability, short borrow fee rate), daily data (short volume, fails-to-deliver) in the middle, and the slowest updated data (short interest) at …WebAUPH opened at $9.06 on Friday. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.07 and a 1 year high of $12.43. The stock’s 50 day simple moving average is $7.93 and its 200 day simple ...Aurinia Pharmaceuticals ( NASDAQ: AUPH) soared 6.7% amid takeover speculation. The Aurinia ( AUPH) stock surge comes amid a report that a Gilead Sciences ( GILD) corporate jet made a trip to ...
Aurinia ( AUPH) shares have climbed ~59.7% in the year so far despite a ~2% decline over the past 30 days. The stock has added ~5.8% in the post-market with ~1.5M shares changing hands compared to ...Mar 23, 2023 · For fiscal 2023, the company expects LUPKYNIS revenue to be between $120 million and $140 million, representing annual growth of 15.4% to 34.6% in terms of net product sales. While analysts expect ... AUPH ($8.23) is undervalued by 7.05% relative to our estimate of its Fair Value price of $8.85 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safetyInstagram:https://instagram. binary forexdaily stock moversgainer loser stockis apple stock a buy Despite upbeat remarks from its chief executive ahead of the earnings, Aurinia’s (NASDAQ:AUPH) 2022 sales guidance fell short of expectations as net revenue for the year dropped ~9% YoY to $45 ...Oct 22, 2021 · Aurinia ( AUPH) shares have climbed ~59.7% in the year so far despite a ~2% decline over the past 30 days. The stock has added ~5.8% in the post-market with ~1.5M shares changing hands compared to ... stocks gainers todaybest crypto bot trading platform Nursing is an excellent career path if you’re interested in working in the healthcare industry and strive to provide quality care to patients. If you’re short on time or worry that attending a brick-and-mortar school isn’t possible, one alt...A high-level overview of Aurinia Pharmaceuticals Inc. (AUPH) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and … cramer nvda Affimed saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 1,640,000 shares, a decline of 24.1% from the October 31st total of 2,160,000 shares. Based on an average daily volume of 562,700 shares, the short-interest ratio is currently 2.9 days. View Affimed's Short Interest.TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comAurinia Pharmaceuticals last released its quarterly earnings results on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.08. The business earned $54.52 million during the quarter, compared to the consensus estimate of $38.41 million.